Copper-catalyzed synthesis achieved high enantioselectivity for aryl alkyl sulfilimines in diverse reactions, suggesting broad application in drug development.
Currently, most sulfoximine clinical candidates feature both S-aryl and S-alkyl substituents. The asymmetric synthesis of these compounds typically relies on oxidizing corresponding enantioenriched sulfilimines. Herein, we describe an effective catalytic system comprising CuI and an azabicyclo[2.2.1] carboxylic acid-derived amide ligand. This system enables the highly enantioselective coupling of S-alkyl sulfenamides with (hetero)aryl iodides to afford aryl alkyl sulfilimines. A wide range of functionalized (hetero)aryl iodides and S-alkyl sulfenamides are compatible under the reaction conditions, providing an attractive approach for assembling enantioenriched aryl alkyl sulfilimines. The utility of this method is demonstrated by the gram-scale asymmetric synthesis of clinical candidate TNG 260 and the formal asymmetric synthesis of three additional drug candidates.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: